PLC commends Neurelis on their recent FDA approval of extended expiration dating for VALTOCO®

19 October 2020 – PLC commends Neurelis on their recent FDA approval of extended expiration dating for VALTOCO^®. PLC has supported the clinical development and regulatory pathway of VALTOCO from its early development phase and continues to provide clinical oversight of ongoing trials and regulatory support for Neurelis and their drug product development in the US. PLC also supported the development and filing of the Orphan Drug Exclusivity for VALTOCO to the US FDA.

NEURELIS ANNOUNCES FDA APPROVAL OF EXTENDED EXPIRATION DATING FOR VALTOCO® (DIAZEPAM NASAL SPRAY)

https://neurelis.com/neurelis-news/fda-approval-extended-expiration-dating

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Related Posts

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

Congratulations to Neurelis on their recent NDA approval for seizure rescue treatment VALTOCO® (Diazepam nasal spray)

PLC is proud to announce Izun Pharmaceuticals has received FDA approval of their 510(k) application for Curastie™ Hydrogel Wound Care